Ned Pagliarulo
Lead Editor | @NedPagliaruloNed is a lead editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from the College at Georgetown University.
2122 articles by Ned Pagliarulo
-
Bristol Myers CAR-T therapy cleared by FDA for earlier lymphoma use
June 23, 2022 -
Novartis hunting for sickle cell cure with Precision deal
June 22, 2022 -
Mixed results for PTC Duchenne drug put spotlight on EU approval
June 21, 2022 -
FDA authorizes Pfizer, Moderna COVID-19 vaccines for young children
June 17, 2022 -
Pfizer study results show Paxlovid benefit less clear in lower-risk patients
June 15, 2022 -
Watchdog group cautious on Amylyx's ALS drug benefits, potential cost
June 14, 2022 -
FDA staff supportive of Pfizer, Moderna COVID vaccines in young children
June 13, 2022 -
FDA advisers offer unanimous support to second Bluebird gene therapy
June 10, 2022 -
FDA panel backs Bluebird gene therapy despite safety risks
June 9, 2022 -
Bluebird's future in balance as FDA weighs gene therapy approvals
June 9, 2022 -
ASCO 2022: Gilead's tough weekend, bispecific progress and 'gamma delta' cell therapy
June 6, 2022 -
FDA extends review of Amylyx ALS drug, delaying approval decision
June 3, 2022 -
Former AbbVie executive Severino joins Flagship-backed startup as CEO
June 2, 2022 -
Upstream Bio, a richly funded startup, reveals its lead drug and research plans
June 2, 2022 -
Sage, Biogen drug meets goal in postpartum depression study
June 1, 2022 -
BioMarin delays planned FDA filing for hemophilia gene therapy
May 31, 2022 -
Mirati matches Amgen with updated data for KRAS-blocking cancer drug
May 26, 2022 -
3 cancer drug studies to watch at next month's ASCO meeting
May 26, 2022 -
Former Editas CEO Bosley joins UK venture capital firm
May 26, 2022 -
FDA starts clock on review of CSL, UniQure gene therapy
May 25, 2022 -
Springworks shares fall despite drug trial's success
May 24, 2022 -
Pfizer, Lilly bolster cases for experimental ulcerative colitis drugs
May 24, 2022 -
Concert drug helps regrow hair in study, boosting shares
May 23, 2022 -
Bayer backs out of Atara cell therapy deal
May 20, 2022 -
Ultragenyx strikes deal with struggling Abeona for rare disease gene therapy
May 17, 2022